Tolerability and Clinical Efficacy of Letermovir for Secondary Cytomegalovirus (CMV) Prophylaxis After Solid Organ Transplantation (WTC 2025) - Jul 30, 2025 - Abstract #P2.05.5; Pres time: Aug 4, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; "*Purpose: Alternative medications to prevent relapsing CMV infection in solid organ transplants are needed due to the potential for adverse effects of valganciclovir. LET is generally safe and well tolerated for CMV secondary PPX, however breakthrough CMV disease can occur in patients with lower lymphocyte counts."
Clinical • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Neutropenia • Solid Organ Transplantation • Transplantation
|
|
J. K. Chow; W. Perry; A. Chami; D. Denofrio; I. Rajapreyar; D. R. Snydman
|